MCID: VRL011
MIFTS: 61

Viral Infectious Disease

Categories: Infectious diseases

Aliases & Classifications for Viral Infectious Disease

MalaCards integrated aliases for Viral Infectious Disease:

Name: Viral Infectious Disease 12 15
Arbovirus Infections 43 17 71
Virus Infection 12 54
Virus Diseases 43 71
Viral Disease 12 17
Viral Infections 42
Virus Infections 15
Viral Infection 12

Classifications:



External Ids:

Disease Ontology 12 DOID:934
NCIt 49 C3439 C34396
SNOMED-CT 67 34014006 40610006
UMLS 71 C0003723 C0042769

Summaries for Viral Infectious Disease

MedlinePlus : 42 Viruses are very tiny germs. They are made of genetic material inside of a protein coating. Viruses cause familiar infectious diseases such as the common cold, flu and warts. They also cause severe illnesses such as HIV/AIDS, smallpox, and Ebola. Viruses are like hijackers. They invade living, normal cells and use those cells to multiply and produce other viruses like themselves. This can kill, damage, or change the cells and make you sick. Different viruses attack certain cells in your body such as your liver, respiratory system, or blood. When you get a virus, you may not always get sick from it. Your immune system may be able to fight it off. For most viral infections, treatments can only help with symptoms while you wait for your immune system to fight off the virus. Antibiotics do not work for viral infections. There are antiviral medicines to treat some viral infections. Vaccines can help prevent you from getting many viral diseases.

MalaCards based summary : Viral Infectious Disease, also known as arbovirus infections, is related to chronic active epstein-barr virus infection and bell's palsy, and has symptoms including fever, pruritus and pathological conditions, signs and symptoms. An important gene associated with Viral Infectious Disease is IFNA1 (Interferon Alpha 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Pseudoephedrine and Ephedrine have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and testes, and related phenotypes are Strongly decreased CFP-tsO45G cell surface transport and hematopoietic system

Disease Ontology : 12 A disease by infectious agent that results in infection, has material basis in Viruses.

Wikipedia : 74 A viral disease (or viral infection, or infectious disease) occurs when an organism's body is invaded by... more...

Related Diseases for Viral Infectious Disease

Diseases related to Viral Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2417)
# Related Disease Score Top Affiliating Genes
1 chronic active epstein-barr virus infection 35.2 IL2 IL10 IFNG
2 bell's palsy 33.7 MX1 IFNA1 CD40LG CD4
3 rabies 33.6 TLR3 MX1 IRF7 IRF3 IFNA1 DDX58
4 intermediate uveitis 33.6 TNF IL2 IL10 IFNG CCR5
5 poliomyelitis 33.5 TNF IL10 IFNG CD40LG CD4
6 chikungunya 33.5 TNF TLR7 MAVS DDX58
7 chickenpox 33.5 TNF TLR3 IL2 IL10 IFNG CD40LG
8 mumps 33.5 TNF TLR3 MX1 IL2 IL10 IFNG
9 rubella 33.5 TNF TLR3 IL2 IL10 IFNG IFNB1
10 hepatitis a 33.5 TNF TLR3 MAVS IL2 IL10 IFNG
11 measles 33.5 TNF TLR7 TLR3 IRF7 IRF3 IL2
12 lymphocytic choriomeningitis 33.4 MAVS IRF3 DDX58
13 biliary atresia 33.3 TLR3 MX1 IFNG GPT
14 tick-borne encephalitis 33.3 TLR3 IL10 IFNB1 GPT DDX58 CCR5
15 tonsillitis 33.3 TNF TLR3 IL2 IL10 IFNG
16 aphthous stomatitis 33.3 TNF IL2 IL10 IFNG
17 staphylococcal toxic shock syndrome 33.2 TNF IFNG
18 optic neuritis 33.2 TNF IL10 CCR5
19 newcastle disease 33.1 TNF TLR3 IRF7 IRF3 IFNB1 IFNA1
20 anogenital venereal wart 33.1 TLR7 TLR3 IL2 IFNA1 CD4
21 venezuelan equine encephalitis 33.1 IRF7 IFNG IFNB1 IFNA1
22 west nile encephalitis 33.1 TLR7 CD40LG CD4 CCR5
23 lassa fever 33.1 IRF3 IFIH1 DDX58 CD40LG
24 hepatitis e 33.1 TNF TLR3 IFNG GPT DDX58 CD40LG
25 crimean-congo hemorrhagic fever 33.1 TNF MX1 GPT DDX58
26 hepatitis d 33.1 IFNA2 IFNA1 GPT CD40LG
27 hand, foot and mouth disease 33.1 TLR7 TLR3 IL10 IFNG DDX58
28 hantavirus hemorrhagic fever with renal syndrome 33.1 TNF MX1 CD40LG CD4
29 herpes simplex 33.1 TNF TLR3 IRF7 IRF3 IFNB1 IFNA1
30 japanese encephalitis 33.1 TNF TLR7 TLR3 IFNB1
31 progressive multifocal leukoencephalopathy 33.1 TNF IL2 IFNB1 CD40LG CD4
32 vaccinia 33.1 TNF IRF7 IRF3 IL2 IFNB1 IFNA1
33 dengue disease 33.1 TNF IFNB1 GPT CD40LG
34 yellow fever 33.1 IRF7 IFNB1 CD40LG CCR5
35 common cold 33.1 TNF TLR3 IL10 IFNA2 CD4
36 hepatitis b 33.1 TNF TLR3 MX1 IFNG IFNB1 IFNA2
37 nasopharyngitis 33.1 TNF GPT CD4
38 subacute sclerosing panencephalitis 33.0 TNF TLR3 MX1 IL2 IL10 IFNG
39 aicardi-goutieres syndrome 33.0 TLR7 TLR3 MX1 MAVS IRF7 IRF3
40 smallpox 33.0 TNF ITIH4 IL2 IFNG
41 herpangina 33.0 TNF TLR7 TLR3 IL2 IL10 IFNA1
42 herpes zoster 33.0 TNF IL2 IL10 IFNG IFNA2 IFNA1
43 influenza 33.0 TNF TLR7 TLR3 MX1 MAVS IRF7
44 human immunodeficiency virus infectious disease 33.0 TNF TLR7 MX1 ITIH4 IL2 IL10
45 hepatitis c 33.0 TNF TLR3 MX1 MAVS IRF7 IRF3
46 tropical spastic paraparesis 32.9 IL2 IL10 IFNG
47 bolivian hemorrhagic fever 32.9 IRF3 DDX58
48 omenn syndrome 32.8 TNF IL10 IFNG CD40LG CD4
49 pleural disease 32.7 TNF IFNG CD4
50 eczema herpeticum 32.4 IRF7 IRF3 IFNG

Graphical network of the top 20 diseases related to Viral Infectious Disease:



Diseases related to Viral Infectious Disease

Symptoms & Phenotypes for Viral Infectious Disease

UMLS symptoms related to Viral Infectious Disease:


fever, pruritus, pathological conditions, signs and symptoms

GenomeRNAi Phenotypes related to Viral Infectious Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Strongly decreased CFP-tsO45G cell surface transport GR00360-A-2 9.1 CCR5 GPT IFIH1 MAVS TLR3 TLR7

MGI Mouse Phenotypes related to Viral Infectious Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.2 CCR5 CD4 CD40LG DDX58 IFIH1 IFNB1
2 cellular MP:0005384 10.18 CCR5 CD4 CD40LG DDX58 IFIH1 IFNG
3 homeostasis/metabolism MP:0005376 10.13 CCR5 CD4 CD40LG DDX58 IFIH1 IFNB1
4 immune system MP:0005387 10.03 CCR5 CD4 CD40LG DDX58 IFIH1 IFNB1
5 digestive/alimentary MP:0005381 9.97 CCR5 CD4 DDX58 IFNG IL10 IL2
6 liver/biliary system MP:0005370 9.56 CCR5 DDX58 IFIH1 IFNG IL10 IL2
7 neoplasm MP:0002006 9.28 CCR5 DDX58 IFNB1 IFNG IL10 IL2

Drugs & Therapeutics for Viral Infectious Disease

Drugs for Viral Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 653)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pseudoephedrine Approved Phase 4 90-82-4 7028
2
Ephedrine Approved Phase 4 299-42-3 9294
3
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
4
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
5
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
6
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
7
Bevacizumab Approved, Investigational Phase 4 216974-75-3
8
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
9
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
10
Cytarabine Approved, Experimental, Investigational Phase 4 147-94-4, 65-46-3 6253
11
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
12
Racepinephrine Approved Phase 4 329-65-7 838
13
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
14
Pancrelipase Approved, Investigational Phase 4 53608-75-6
15
Lopinavir Approved Phase 4 192725-17-0 92727
16
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
17
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
18
Montelukast Approved Phase 4 158966-92-8 5281040
19
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
20
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
21
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
22
Didanosine Approved Phase 4 69655-05-6 50599
23
Metformin Approved Phase 4 657-24-9 14219 4091
24
Thyme Approved Phase 4
25
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
26
Simvastatin Approved Phase 4 79902-63-9 54454
27
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
28
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
29
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
30
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
31
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
32
Polyestradiol phosphate Approved Phase 4 28014-46-2
33
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
34
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
35
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
36
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
37
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
38
Petrolatum Approved, Investigational Phase 4 8009-03-8
39
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
40
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
41
Foscarnet Approved Phase 4 4428-95-9, 63585-09-1 3415
42
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
43
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
44
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
45
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
46
Menthol Approved Phase 4 2216-51-5 16666
47
Clarithromycin Approved Phase 4 81103-11-9 84029
48
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
49
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
50
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825

Interventional clinical trials:

(show top 50) (show all 2014)
# Name Status NCT ID Phase Drugs
1 Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial. Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
2 Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial Unknown status NCT00663182 Phase 4 Entecavir
3 A Double Blind Randomised Placebo Controlled Trial of Montelukast in the Treatment of Acute Persistent Cough in Young People and Adults in Primary Care Unknown status NCT01279668 Phase 4 Montelukast;Placebo
4 A Randomised Controlled Trial of a Strategy of Switching to Boosted PI Monotherapy Versus Continuing Combination ART for the Long-term Management of HIV-1 Infected Patients Who Have Achieved Sustained Virological Suppression on HAART Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
5 Polyomavirus BK Nephropathy After Renal Transplantation: Randomized Clinical Trial to Demonstrate That Switching to mTOR Inhibitor is More Effective Than a Reduction of Immunosuppressive Therapy Unknown status NCT01289301 Phase 4 mTOR inhibitor (everolimus);cyclosporine or tacrolimus
6 Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children Unknown status NCT00494624 Phase 4 prednisolone
7 A Multicenter, Open-label, Prospective Study to Evaluate Antiviral Efficacy and Safety of Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4 Entecavir + Tenofovir (MDR group)
8 The Effectiveness and Feasibility of Using Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus-drug Test and Follow-up Study Unknown status NCT01312012 Phase 4 antiviral therapy
9 Effects of Antihypertensive Treatment on Cardiac Remodelling and Metabolic Profile in HIV Infected Patients: Randomized Longitudinal Study With Candesartan Versus Lercanidipine Unknown status NCT00564057 Phase 4 candesartan;lercanidipine
10 Phase IV Study of the Efficacy of Entecavir in Patients With Chronic Hepatitis B Virus Infection and Persistently Normal Alanine Aminotransferase Unknown status NCT01833611 Phase 4 Entecavir;placebo
11 A Study of Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection Unknown status NCT00939068 Phase 4 Telbivudine
12 Antiviral and Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) Virus Pneumonia: Multi-centre, Prospective, Randomized Controlled Study Unknown status NCT00936013 Phase 4 oseltamivir;oseltamivir and chinese medicinal herbs
13 Double-blind, Randomized, Placebo-controlled Clinical Study Investigating Efficacy and Safety of Arbidol (Umifenovir) in Treatment and Prophylaxis of Influenza and Common Cold. Unknown status NCT01651663 Phase 4 Arbidol (Umifenovir);Arbidol (Umifenovir)
14 A Prospective, Open-label, Multicenter Study of Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
15 Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
16 Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial Unknown status NCT01649245 Phase 4 Reiferon retard
17 An Open-label, Multi-center, Randomized Study Comparing the Effects of Oral Hypoglycemic Agents on Viral Kinetics of Chronic Hepatitis C Patients Receiving Pegylated Interferon Alfa 2b Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
18 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4 dehydroepiandrosterone
19 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled,Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
20 Fractional Concentration of Exhaled NO(FeNO) to Direct The Treatment of Sub-acute Cough:A Prospective, Open Label, Randomized and Placebo-Controlled Trial Unknown status NCT02655562 Phase 4 Montelukast
21 Management of Active and Established Corneal Neovascularisation to Prevent Visual Impairment Unknown status NCT02594423 Phase 4 Bevacizumab
22 Direct Observed Therapy With Ledipasvir/Sofosbuvir in Treatment-naïve Patients With Chronic Genotype 1 HCV (Hepatitis C Virus) Infection Receiving Opiate Substitution Therapy Unknown status NCT02638233 Phase 4 Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)
23 Bronchiolitis All-study, SE-Norway What is the Optimal Inhalation Treatment for Children 0-12 Months With Acute Bronchiolitis? Unknown status NCT00817466 Phase 4 Racemic adrenaline;Isotonic saline
24 1-Year Longitudinal Follow-up Study of Serologic Responses to 7-valent Pneumococcal Conjugated Vaccination and Opsonophagocytic Activities for Streptococcus Pneumoniae Among Patients With Human Immunodeficiency Virus Infection Unknown status NCT00885625 Phase 4
25 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
26 Randomised Double Blind Placebo Controlled Multicenter Study for Evaluation of Clinical Efficacy and Safety of Ingavirin 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults. Completed NCT03154515 Phase 4 Ingavirin;Placebo
27 Dose Study of Antithymocyteglobulin in Haploidentical Hematopoietic Stem Cell Transplantation for Acute Graft-versus-host Disease Prophylaxis Completed NCT01883180 Phase 4 ATG
28 Multicentre Double-blind Placebo-controlled Parallel Group Randomized Clinical Trial of Efficacy and Safety of Anaferon in the Treatment of Acute Respiratory Viral Completed NCT03707912 Phase 4 Anaferon;Placebo
29 International Multicenter Double-blind Placebo-Controlled Parallel-Group Randomized Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Acute Respiratory Viral Infections in Children Completed NCT03039621 Phase 4 Ergoferon;Placebo
30 International Multicenter Double-bind Placebo-controlled Randomized Parallel-group Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other Acute Respiratory Viral Infections in Children During the Peaks of Seasonal Morbidity Completed NCT03301155 Phase 4 Anaferon for children;Placebo
31 Direct and Indirect Benefits of Influenza Vaccination in Schools and Households Completed NCT00981513 Phase 4
32 Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy Completed NCT01819792 Phase 4
33 Palatability Testing of a New Paediatric Formulation of Valacyclovir for the Prophylaxis and Treatment of VZV and HSV Infections in Children Completed NCT01682109 Phase 4 Valacyclovir
34 Prevention of RSV Infections in Bone Marrow Transplant Recipients Completed NCT00001903 Phase 4 RSV Polyclonal Immunoglobulin
35 Open, Randomised Study Comparing Preemptive Therapy With Intravenous Ganciclovir With and Without Additional Oral Ganciclovir for CMV Prophylaxis in Immunosuppressed Renal Transplant Patients Receiving Monitoring of CMV Viral Load Completed NCT00373165 Phase 4 Ganciclovir
36 A Phase 4, Multicenter, Open Label Study to Investigate the Efficacy and Safety of an All Oral Combination of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis VALOR-HCV: Veterans Affairs alL Oral Regimen of SOF+RBV in GT2 HCV Completed NCT02128542 Phase 4 Sofosbuvir;RBV
37 Treatment of Recently Acquired Hepatitis C Virus Infection Completed NCT01336010 Phase 4 Peginterferon alfa-2a;Ribavirin
38 Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection Completed NCT01097395 Phase 4 ribavirin
39 Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study Completed NCT01353339 Phase 4 Levofloxacin
40 International Multicenter Double-blind Placebo-controlled Randomized Parallel Group Clinical Trial of Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children Completed NCT02072174 Phase 4 Anaferon for Children
41 Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART Completed NCT01869634 Phase 4 darunavir with ritonavir and fixed-dose viread+emtricitabine daily
42 Randomized Study on the Efficacy and Safety of Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation Completed NCT00383864 Phase 4 Pegylated interferon and ribavirin
43 Pilot Study to Assess the Effect of Prophylactic Antipyretics on Immune Responses and Rates of Fever After 2013-2014 Inactivated Influenza Vaccine (IIV) in Young Children Completed NCT01946594 Phase 4
44 A Randomized Controlled Trial on the Effect of Fever Suppression by Antipyretics on Influenza Completed NCT01891084 Phase 4 Paracetamol;Placebo;Backup NSAID ibuprofen
45 Treatment of Acute Hepatitis C Virus Infection in Injection Drug Users With Pegylated Interferon for 24 Weeks Completed NCT00194480 Phase 4 Pegylated Interferon
46 Safety and Efficacy of Mycophenolic Acid Withdrawal With Conversion to Zortress (Everolimus) in Renal Transplant Recipients With BK Virus Infection Completed NCT01624948 Phase 4 Everolimus;Mycophenolic acid dose reduction
47 Ciprofloxacin for Prevention of BK Infection in Renal Transplant Recipients Completed NCT01789203 Phase 4 Ciprofloxacin;placebo
48 Induction of HBsAg Decline Using an add-on Treatment of Peginterferon Alfa-2a in HBeAg-negative Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogous (PAS) Completed NCT01373684 Phase 4 Peginterferon alfa-2a;Nucleos(t)ide analogue
49 Safety and Immunogenicity of Fluzone® Influenza Virus Vaccine (2006-2007 Formulation) Among Healthy Children Immunized in Fall 2005 With Fluzone Vaccine or Placebo Completed NCT00390884 Phase 4
50 Generic Velpatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Completed NCT03250910 Phase 4 Sofosbuvir and Velpatasvir;Ribavirin

Search NIH Clinical Center for Viral Infectious Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


BISMUTH HYDROXIDE
BISMUTH RESORCIN COMPOUND
bismuth subcarbonate
BISMUTH SUBCARBONATE PWDR
bismuth subcitrate
bismuth subgallate
BISMUTH SUBIODIDE
bismuth subnitrate
BISMUTH SUBNITRATE PWDR
bismuth subsalicylate
BISMUTH-FORMIC-IODIDE
Idoxuridine
Nucleoside Analog Antiviral [EPC]
Ribavirin
Trifluridine

Cochrane evidence based reviews: arbovirus infections

Genetic Tests for Viral Infectious Disease

Anatomical Context for Viral Infectious Disease

MalaCards organs/tissues related to Viral Infectious Disease:

40
Liver, T Cells, Testes, Kidney, Lung, Bone, B Cells

Publications for Viral Infectious Disease

Articles related to Viral Infectious Disease:

(show top 50) (show all 2300)
# Title Authors PMID Year
1
Salivary Gland Diseases. 42
31735235 2020
2
Differences of viral panel positive versus negative by real-time PCR in COPD exacerbated patients. 42
31414643 2019
3
Autophagy and Viral Infection. 42
31728865 2019
4
Seroprevalence of yellow fever, dengue, West Nile and chikungunya viruses in children in Teso South Sub-County, Western Kenya. 61
31712089 2020
5
Ophthalmic manifestations of arbovirus infections in adults. 61
31679764 2020
6
The rise or fall of neglected tropical diseases in East Asia Pacific. 61
31550453 2020
7
Expansion of the Distribution of Aedes albopictus (Diptera: Culicidae): New Records in Northern Argentina and Their Implications From an Epidemiological Perspective. 61
32020186 2020
8
Review of Phytochemical Compounds as Antiviral Agents against Arboviruses from the Genera Flavivirus and Alphavirus. 61
31969106 2020
9
Pan-viral protection against arboviruses by activating skin macrophages at the inoculation site. 61
31969486 2020
10
Immunohistochemical identification of antigens of canine distemper virus in neotropical felids from Southern Brazil. 61
31916410 2020
11
Yellow Fever Virus Reemergence and Spread in Southeast Brazil, 2016-2019. 61
31597773 2019
12
Reliable Serological Diagnostic Tests for Arboviruses: Feasible or Utopia? 61
31864844 2019
13
Identification of B-Cell Epitopes with Potential to Serologicaly Discrimnate Dengue from Zika Infections. 61
31752352 2019
14
Improving immunological insights into the ferret model of human viral infectious disease. 61
31583825 2019
15
The phylogenetic approach for viral infectious disease evolution and epidemiology: An updating review. 61
31243773 2019
16
Endemic Disease Control Agents' perception on the fight against Aedes aegypti and the prevention of arbovirus infections in Brazil. 61
31584945 2019
17
Osteoarticular manifestations of Mayaro virus infection. 61
31361271 2019
18
Efficacy of the combination of superficial shaving with photodynamic therapy for recalcitrant periungual warts. 61
31252143 2019
19
Environmental suitability for Aedes aegypti and Aedes albopictus and the spatial distribution of major arboviral infections in Mexico. 61
31528740 2019
20
Epidemiological Characteristics and Spatial Analysis of Tick-Borne Encephalitis in Jilin Province, China. 61
31074410 2019
21
Diagnostic Performance of Dengue Virus Envelope Domain III in Acute Dengue Infection. 61
31311082 2019
22
Atovaquone Inhibits Arbovirus Replication through the Depletion of Intracellular Nucleotides. 61
30894466 2019
23
Detection of chikungunya virus-specific IgM on laser-cut paper-based device using pseudo-particles as capture antigen. 61
30734316 2019
24
Mycoplasma bovis and viral agents associated with the development of bovine respiratory disease in adult dairy cows. 61
31232526 2019
25
Understanding social inequalities in Zika infection and its consequences: A model of pathways and policy entry-points. 61
30301438 2019
26
Exome-wide search and functional annotation of genes associated in patients with severe tick-borne encephalitis in a Russian population. 61
31122248 2019
27
Implementation of the One Health approach to fight arbovirus infections in the Mediterranean and Black Sea Region: Assessing integrated surveillance in Serbia, Tunisia and Georgia. 61
30724030 2019
28
Emerging and Reemerging Aedes-Transmitted Arbovirus Infections in the Region of the Americas: Implications for Health Policy. 61
30676796 2019
29
Metabolomic Insights into Human Arboviral Infections: Dengue, Chikungunya, and Zika Viruses. 61
30845653 2019
30
Spatiotemporal characteristics and primary influencing factors of typical dengue fever epidemics in China. 61
30922405 2019
31
Fulminant myocarditis associated with severe fever with thrombocytopenia syndrome: a case report. 61
30885147 2019
32
Prevalence of avian influenza, Newcastle disease, and infectious bronchitis viruses in broiler flocks infected with multifactorial respiratory diseases in Iran, 2015-2016. 61
30377950 2019
33
The proportion, origin and pro-inflammation roles of low density neutrophils in SFTS disease. 61
30717709 2019
34
Diagnostic Value of Platelet and Leukocyte Counts in the Differential Diagnosis of Fever in the Returning Traveler. 61
30526735 2019
35
Differential Shedding and Antibody Kinetics of Zika and Chikungunya Viruses, Brazil. 61
30666934 2019
36
Development of an anti-hepatitis B virus (HBV) agent through the structure-activity relationship of the interferon-like small compound CDM-3008. 61
30552008 2019
37
Dengue fever and chikungunya virus infections: identification in travelers in Uganda - 2017. 61
31798935 2019
38
Control of Acute Arboviral Infection by Natural Killer Cells. 61
30709036 2019
39
External Control Viral-Like Particle Construction for Detection of Emergent Arboviruses by Real-Time Reverse-Transcription PCR. 61
31687381 2019
40
Alternative strategies for mosquito-borne arbovirus control. 61
30605475 2019
41
Evidence for Host Epigenetic Signatures Arising From Arbovirus Infections: A Systematic Review. 61
31214179 2019
42
[Pharmacological profiles and clinical effects of amenamevir tablet as treatments for herpes zoster]. 61
30643090 2019
43
In vitro safety and performance evaluation of a seawater solution enriched with copper, hyaluronic acid, and eucalyptus for nasal lavage. 61
31576180 2019
44
Modeling Arboviral Infection in Mice Lacking the Interferon Alpha/Beta Receptor. 61
30625992 2019
45
Arboviruses and the Challenge to Establish Systemic and Persistent Infections in Competent Mosquito Vectors: The Interaction With the RNAi Mechanism. 61
31354527 2019
46
Effectiveness and cost-benefit study to encourage herd owners in a cost sharing vaccination programme against bluetongue serotype-8 in Belgium. 61
30281942 2019
47
Evaluation of the impact of live pig trade network, vaccination coverage and socio-economic factors in the classical swine fever eradication program in Peru. 61
30621896 2019
48
Condition-specific gene co-expression network mining identifies key pathways and regulators in the brain tissue of Alzheimer's disease patients. 61
30598117 2018
49
Estimating the risk of Dengue, Chikungunya and Zika outbreaks in a large European city. 61
30401870 2018
50
The Neglect and Fast Spread of Some Arboviruses: A Note for Healthcare Providers in Nigeria. 61
30400643 2018

Variations for Viral Infectious Disease

Expression for Viral Infectious Disease

Search GEO for disease gene expression data for Viral Infectious Disease.

Pathways for Viral Infectious Disease

Pathways related to Viral Infectious Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 TNF TLR7 TLR3 MX1 MAVS IRF7
2
Show member pathways